Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com reuters.com technologynetworks.com technologynetworks.com.
Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade. IO Biotech will disclose topline results from its Phase III melanoma trial of Cylembio (IO102-IO103)…
Read more